{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2"],"submitter":["Rebiere V"],"pubmed_abstract":["Currently, prognostic models in diffuse large B-cell lymphoma (DLBCL) fail to closely reflect patients' biological, clinical, and survival heterogeneity. We, therefore, assessed the impact of clinical, biological, immunohistochemical (IHC), baseline (0), and interim (after 2 and 4 treatment cycles) PET (PET0, PET2, and PET4) data not yet included in any scoring system on DLBCL outcome. The analysis was conducted on 89 previously untreated adult patients of the Finistere Observatory Cohort (O.Ly.Fin) with documented DLBCL, recruited between January 2010 and December 2017, with progression-free survival (PFS) and overall survival (OS) as primary and secondary endpoints, respectively. Seventy-eight patients were treated with rituximab, cyclophosphamide, hydroxyadriamycin, vincristine, and pre"],"journal":["Frontiers in nuclear medicine"],"pagination":["829138"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11440974"],"repository":["biostudies-literature"],"pubmed_title":["Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma."],"pmcid":["PMC11440974"],"pubmed_authors":["Salaun PY","Rebiere V","Le Bris AS","Malou M","Salmon F","Berthou C","Abgral R","Maajem M","Quintin-Roue I","Le Calloch R","Raj L","Samaison L","Eveillard JR","Tempescul A","Bourhis D","Saad H","Ianotto JC"],"additional_accession":[]},"is_claimable":false,"name":"Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.","description":"Currently, prognostic models in diffuse large B-cell lymphoma (DLBCL) fail to closely reflect patients' biological, clinical, and survival heterogeneity. We, therefore, assessed the impact of clinical, biological, immunohistochemical (IHC), baseline (0), and interim (after 2 and 4 treatment cycles) PET (PET0, PET2, and PET4) data not yet included in any scoring system on DLBCL outcome. The analysis was conducted on 89 previously untreated adult patients of the Finistere Observatory Cohort (O.Ly.Fin) with documented DLBCL, recruited between January 2010 and December 2017, with progression-free survival (PFS) and overall survival (OS) as primary and secondary endpoints, respectively. Seventy-eight patients were treated with rituximab, cyclophosphamide, hydroxyadriamycin, vincristine, and pre","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-29T03:07:05.196Z","creation":"2025-04-04T08:21:19.8Z"},"accession":"S-EPMC11440974","cross_references":{"pubmed":["39354989"],"doi":["10.3389/fnume.2022.829138"]}}